Quality-by-design risk assessment of topical formulation variability
- Author
- Lien Taevernier (UGent) , Sven Detroyer, Lieselotte Veryser (UGent) and Bart De Spiegeleer (UGent)
- Organization
- Keywords
- Cyclic depsipeptide mycotoxins, Fusafungine, Enniatins, Excipient variability, Quality-by-Design (QbD), Transmucosal Franz diffusion cell, Plasma concentration after buccal application
Downloads
-
2015 189b Poster 26th PBA Tbilisi Georgia Lien Taevernier.pdf
- full text
- |
- open access
- |
- |
- 501.93 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-6855247
- MLA
- Taevernier, Lien, et al. “Quality-by-Design Risk Assessment of Topical Formulation Variability.” Pharmaceutical and Biomedical Analysis, 26th International Symposium, Abstracts, 2015.
- APA
- Taevernier, L., Detroyer, S., Veryser, L., & De Spiegeleer, B. (2015). Quality-by-design risk assessment of topical formulation variability. Pharmaceutical and Biomedical Analysis, 26th International Symposium, Abstracts. Presented at the 26th International symposium on Pharmaceutical and Biomedical Analysis (PBA 2015), Tbilisi, Georgia.
- Chicago author-date
- Taevernier, Lien, Sven Detroyer, Lieselotte Veryser, and Bart De Spiegeleer. 2015. “Quality-by-Design Risk Assessment of Topical Formulation Variability.” In Pharmaceutical and Biomedical Analysis, 26th International Symposium, Abstracts.
- Chicago author-date (all authors)
- Taevernier, Lien, Sven Detroyer, Lieselotte Veryser, and Bart De Spiegeleer. 2015. “Quality-by-Design Risk Assessment of Topical Formulation Variability.” In Pharmaceutical and Biomedical Analysis, 26th International Symposium, Abstracts.
- Vancouver
- 1.Taevernier L, Detroyer S, Veryser L, De Spiegeleer B. Quality-by-design risk assessment of topical formulation variability. In: Pharmaceutical and Biomedical Analysis, 26th International symposium, Abstracts. 2015.
- IEEE
- [1]L. Taevernier, S. Detroyer, L. Veryser, and B. De Spiegeleer, “Quality-by-design risk assessment of topical formulation variability,” in Pharmaceutical and Biomedical Analysis, 26th International symposium, Abstracts, Tbilisi, Georgia, 2015.
@inproceedings{6855247, author = {{Taevernier, Lien and Detroyer, Sven and Veryser, Lieselotte and De Spiegeleer, Bart}}, booktitle = {{Pharmaceutical and Biomedical Analysis, 26th International symposium, Abstracts}}, keywords = {{Cyclic depsipeptide mycotoxins,Fusafungine,Enniatins,Excipient variability,Quality-by-Design (QbD),Transmucosal Franz diffusion cell,Plasma concentration after buccal application}}, language = {{eng}}, location = {{Tbilisi, Georgia}}, title = {{Quality-by-design risk assessment of topical formulation variability}}, year = {{2015}}, }